CoChat

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers

Open access
Sabari, Joshua K, Offin, Michael, Stephens, Dennis, Ni, Andy, Lee, Adrian, Pavlakis, Nick, Clarke, Stephen, Diakos, Connie I, Datta, Sutirtha, Tandon, Nidhi, Martinez, Andres, Myers, Mackenzie L, Makhnin, Alex, Leger, Ysleni, Yu, Helena A, Paik, Paul K, Chaft, Jamie E, Kris, Mark G, Jeon, Jeong O, Borsu, Laetitia A, Ladanyi, Marc, Arcila, Maria E, Hernandez, Jennifer, Henderson, Samantha, Shaffer, Tristan, Garg, Kavita, DiPasquo, Dan, Raymond, Christopher K, Lim, Lee P, Li, Mark, Hellmann, Matthew D, Drilon, Alexander, Riely, Gregory J, Rusch, Valerie W, Jones, David R, Rimner, Andreas, Rudin, Charles M, Isbell, James M, Li, Bob T · 2019 · JNCI: Journal of the National Cancer Institute
Cited by 123

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is commercially available and increasingly adopted in clinical practice despite a paucity of prospective data to support its use. METHODS: Patients with advanced lung cancers who had no known oncogenic driver or developed resistance to current targeted therapy (n = 210) underwent plasma NGS, targeting 21 genes. A subset of patients had concurrent tissue NGS testing using a 468-gene panel (n = 106). Oncogenic driver detection, test turnaround time (TAT), concordance, and treatment response guided by plasma NGS were measured. All statistical tests were two-sided. RESULTS: Somatic mutations were detected in 64.3% (135/210) of patients. ctDNA detection was lower in patients who were on systemic therapy at the time of plasma collection compared with those who were not (30/70, 42.9% vs 105/140, 75.0%; OR = 0.26, 95% CI = 0.1 to 0.5, P < .001). The median TAT of plasma NGS was shorter than tissue NGS (9 vs 20 days; P < .001). Overall concordance, defined as the proportion of patients for whom at least one identical genomic alteration was identified in both tissue and plasma, was 56.6% (60/106, 95% CI = 46.6% to 66.2%). Among patients who tested plasma NGS positive, 89.6% (60/67; 95% CI = 79.7% to 95.7%) were also concordant on tissue NGS and 60.6% (60/99; 95% CI = 50.3% to 70.3%) vice versa. Patients who tested plasma NGS positive for oncogenic drivers had tissue NGS concordance of 96.1% (49/51, 95% CI = 86.5% to 99.5%), and directly led to matched targeted therapy in 21.9% (46/210) with clinical response. CONCLUSIONS: Plasma ctDNA NGS detected a variety of oncogenic drivers with a shorter TAT compared with tissue NGS and matched patients to targeted therapy with clinical response. Positive findings on plasma NGS were highly concordant with tissue NGS and can guide immediate therapy; however, a negative finding in plasma requires further testing. Our findings support the potential incorporation of plasma NGS into practice guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djy156

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 123

Metadata

Authors
Sabari, J. K., Offin, M., Stephens, D., Ni, A., Lee, A., Pavlakis, N., Clarke, S., Diakos, C. I., Datta, S., Tandon, N., Martinez, A., Myers, M. L., Makhnin, A., Leger, Y., Yu, H. A., Paik, P. K., Chaft, J. E., Kris, M. G., Jeon, J. O., Borsu, L. A., Ladanyi, M., Arcila, M. E., Hernandez, J., Henderson, S., Shaffer, T., Garg, K., DiPasquo, D., Raymond, C. K., Lim, L. P., Li, M., Hellmann, M. D., Drilon, A., Riely, G. J., Rusch, V. W., Jones, D. R., Rimner, A., Rudin, C. M., Isbell, J. M., & Li, B. T.
Venue
JNCI: Journal of the National Cancer Institute
Published
2018-11-28
Volume
111
Issue
6
Pages
575-583
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2902173562
Cited by
123
References
8
FWCI
10.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. https://app.cochat.ai/papers/10.1093/jnci/djy156
The paper
Sabari, J. K., Offin, M., Stephens, D., Ni, A., Lee, A., Pavlakis, N., Clarke, S., Diakos, C. I., Datta, S., Tandon, N., Martinez, A., Myers, M. L., Makhnin, A., Leger, Y., Yu, H. A., Paik, P. K., Chaft, J. E., Kris, M. G., Jeon, J. O., . . . Li, B. T. (2019). A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.